Lesinurad

Chemical formula: C₁₇H₁₄BrN₃O₂S  Molecular mass: 404.28 g/mol  PubChem compound: 53465279

Therapeutic indications

Lesinurad is indicated for:

Hyperuricaemia in gout

Population group: only adults (18 years old or older)

Lesinurad, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lesinurad is contraindicated in the following cases:

Tumour lysis syndrome, Lesch-Nyhan syndrome

at least one of
Tumor lysis syndrome
Lesch-Nyhan syndrome

Severe renal impairment, end-stage renal disease, kidney transplant recipients, dialysis

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)
Renal dialysis
Transplanted kidney present

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: ZURAMPIC Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈